278 related articles for article (PubMed ID: 23474756)
1. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
Lee-Sherick AB; Eisenman KM; Sather S; McGranahan A; Armistead PM; McGary CS; Hunsucker SA; Schlegel J; Martinson H; Cannon C; Keating AK; Earp HS; Liang X; DeRyckere D; Graham DK
Oncogene; 2013 Nov; 32(46):5359-68. PubMed ID: 23474756
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK
Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638
[TBL] [Abstract][Full Text] [Related]
3. Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).
Krause S; Pfeiffer C; Strube S; Alsadeq A; Fedders H; Vokuhl C; Loges S; Waizenegger J; Ben-Batalla I; Cario G; Möricke A; Stanulla M; Schrappe M; Schewe DM
Blood; 2015 Jan; 125(5):820-30. PubMed ID: 25428221
[TBL] [Abstract][Full Text] [Related]
4. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.
Cummings CT; Linger RM; Cohen RA; Sather S; Kirkpatrick GD; Davies KD; DeRyckere D; Earp HS; Graham DK
Oncotarget; 2014 Nov; 5(21):10434-45. PubMed ID: 25372020
[TBL] [Abstract][Full Text] [Related]
5. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.
Keating AK; Kim GK; Jones AE; Donson AM; Ware K; Mulcahy JM; Salzberg DB; Foreman NK; Liang X; Thorburn A; Graham DK
Mol Cancer Ther; 2010 May; 9(5):1298-307. PubMed ID: 20423999
[TBL] [Abstract][Full Text] [Related]
7. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D
Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029
[TBL] [Abstract][Full Text] [Related]
8. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.
Christoph S; Deryckere D; Schlegel J; Frazer JK; Batchelor LA; Trakhimets AY; Sather S; Hunter DM; Cummings CT; Liu J; Yang C; Kireev D; Simpson C; Norris-Drouin J; Hull-Ryde EA; Janzen WP; Johnson GL; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2013 Nov; 12(11):2367-77. PubMed ID: 23997116
[TBL] [Abstract][Full Text] [Related]
9. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
[TBL] [Abstract][Full Text] [Related]
10. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
Levis M; Allebach J; Tse KF; Zheng R; Baldwin BR; Smith BD; Jones-Bolin S; Ruggeri B; Dionne C; Small D
Blood; 2002 Jun; 99(11):3885-91. PubMed ID: 12010785
[TBL] [Abstract][Full Text] [Related]
11. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.
Waizenegger JS; Ben-Batalla I; Weinhold N; Meissner T; Wroblewski M; Janning M; Riecken K; Binder M; Atanackovic D; Taipaleenmaeki H; Schewe D; Sawall S; Gensch V; Cubas-Cordova M; Seckinger A; Fiedler W; Hesse E; Kröger N; Fehse B; Hose D; Klein B; Raab MS; Pantel K; Bokemeyer C; Loges S
Leukemia; 2015 Mar; 29(3):696-704. PubMed ID: 25102945
[TBL] [Abstract][Full Text] [Related]
12. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
13. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.
Linger RM; DeRyckere D; Brandão L; Sawczyn KK; Jacobsen KM; Liang X; Keating AK; Graham DK
Blood; 2009 Sep; 114(13):2678-87. PubMed ID: 19643988
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma.
Li Y; Wang X; Bi S; Zhao K; Yu C
Biochem Biophys Res Commun; 2015 Feb; 457(3):461-6. PubMed ID: 25596315
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
17. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.
Ben-Batalla I; Schultze A; Wroblewski M; Erdmann R; Heuser M; Waizenegger JS; Riecken K; Binder M; Schewe D; Sawall S; Witzke V; Cubas-Cordova M; Janning M; Wellbrock J; Fehse B; Hagel C; Krauter J; Ganser A; Lorens JB; Fiedler W; Carmeliet P; Pantel K; Bokemeyer C; Loges S
Blood; 2013 Oct; 122(14):2443-52. PubMed ID: 23982172
[TBL] [Abstract][Full Text] [Related]
18. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
[TBL] [Abstract][Full Text] [Related]
20. Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.
Linger RM; Lee-Sherick AB; DeRyckere D; Cohen RA; Jacobsen KM; McGranahan A; Brandão LN; Winges A; Sawczyn KK; Liang X; Keating AK; Tan AC; Earp HS; Graham DK
Blood; 2013 Aug; 122(9):1599-609. PubMed ID: 23861246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
